GLP-1s and the heart: heart rate, blood pressure and the SELECT trial

Reviewed 15 sourcesPublished by PepVault

GLP-1s lift resting heart rate 1 to 4 beats a minute and lower blood pressure. The four labels side by side, plus SELECT, SURPASS-CVOT and SUMMIT on the heart.

A blank white sheet, a coffee mug, oranges and mint on a wooden table, a hand in a grey sleeve
Last reviewed
Sources
15
Questions
7
Compounds
2

The short answer

GLP-1s lower blood pressure, lift resting heart rate by about 1 to 4 beats a minute, and on the bigger question protect the heart. In SELECT, Wegovy cut heart attacks, strokes and heart deaths by 20% in people with heart disease and no diabetes. Wegovy, Ozempic and Mounjaro now carry a heart-protection use on their labels; Zepbound does not yet.

  • Heart rate: up 2 to 3 beats a minute on Ozempic, 1 to 4 on Wegovy, 2 to 4 on Mounjaro and 1 to 3 on Zepbound, by each label; only Wegovy's lists it as a warning to monitor.
  • Blood pressure: the top number fell 6.2 mmHg on Wegovy 2.4 mg and 6.6 to 7.7 on Zepbound in SURMOUNT-1, against about 1 on placebo.
  • SELECT: 6.5% on semaglutide 2.4 mg against 8.0% on placebo had a heart attack, stroke or heart death over about 40 months (hazard ratio 0.80).
  • Heart failure: tirzepatide (SUMMIT) and semaglutide (STEP-HFpEF) helped obesity-related heart failure in trials, but as of November 20, 2026 no US label carries a heart-failure use.

Every number checked at its primary source · · 15 sources · How we research

Evidence: Phase 3 double-blind outcome trials behind three FDA heart indications (SUSTAIN-6 and SELECT against placebo for semaglutide, SURPASS-CVOT against dulaglutide for tirzepatide); heart rate and blood pressure from the four labels' trial pools; two phase 3 heart failure trials and a post hoc pool, with no heart-failure indication yet; the pacemaker-receptor finding is from monkey and human tissue samples.

A blank white sheet, a coffee mug, oranges and mint on a wooden table, a hand in a grey sleeve

Do GLP-1s raise your heart rate?

Yes, by a few beats a minute, and every label says so. A GLP-1 (pepvault.app/glossary/glp-1; a drug that copies the gut hormone that slows the stomach and quiets appetite) acts on receptors well beyond the gut: in monkey and human tissue samples, the GLP-1 receptor sits in the cells of the sinoatrial node, the heart's own pacemaker15. Here is each label's figure, as of November 20, 2026:

LabelAverage rise in heart rateOn placeboWhat else the label says
Ozempic (semaglutide 0.5 and 1 mg)2 to 3 beats a minute1Down 0.31Listed under adverse reactions; QTc (the heart's electrical reset) not prolonged at doses up to 1.5 mg1
Wegovy (semaglutide 2.4 mg)1 to 4 at rest, beyond placebo2The comparisonA warning (section 5.9): a rise of 20 or more beats at any visit in 26% against 16% on placebo; check heart rate at regular intervals2
Mounjaro (tirzepatide)2 to 4 beats a minute3Up 13Fast-pulse episodes (a rise of 15 or more) in 4.6%, 5.9% and 10% at 5, 10 and 15 mg, against 4.3% on placebo; "clinical relevance … uncertain"3
Zepbound (tirzepatide)1 to 3 beats a minute4No rise4Listed under adverse reactions4

On Zepbound the rise grows with the dose: at 5 mg the pulse sat 0.5 beats above placebo at 72 weeks, at 10 and 15 mg 2.2 and 2.5 beats above4. And a higher dose does not always mean a bigger rise: in the trial of Wegovy 7.2 mg, resting heart rate rose 0.5 beats against a 0.6 fall on placebo, a gap of 1 beat2. No label gives the week the rise starts. Wegovy's is the only one that tells prescribers to stop the drug if a person's resting heart rate stays up2.

With Apple Health connected, the dose card on PepVault's Today screen shows the day's resting heart rate in its footer, beside sleep, HRV and steps (with Whoop connected, Whoop's recovery line takes that spot). Log it in PepVault

Commonly reported: a resting heart rate a few beats higher. On our reports pages it is a small complaint: a higher resting rate is named in 2 of 41 semaglutide write-ups and 3 of 77 tirzepatide write-ups; one more tirzepatide user names a racing heart, and one a lower resting rate.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

With Apple Health connected, the dose card on PepVault's Today screen shows the day's resting heart rate in its footer, beside sleep, HRV and steps (with Whoop connected, Whoop's recovery line takes that spot).

Download on the App Store

7 days free on the yearly plan for new subscribers.

How much do GLP-1s lower blood pressure?

By about 5 to 8 points on the top number (systolic pressure, the push while the heart beats) in the main weight trials against about 1 point on placebo, and 10 on Wegovy 7.2 mg. The two weight-loss labels print the numbers; Ozempic's and Mounjaro's give none13.

Trial on the labelDrug and doseSystolic change on the drugOn placebo
Study 2 (STEP 1), adults with obesity, 68 weeksWegovy 2.4 mg-6.2 mmHg2-1.12
Study 8 (STEP UP), adults with obesity, 72 weeksWegovy 7.2 mg-10.1 mmHg2-4.82
SELECT, heart disease and no diabetes, 104 weeksWegovy 2.4 mg-3.8 mmHg2-0.52
SURMOUNT-1, adults with obesity, 72 weeksZepbound 5, 10, 15 mg-6.6, -7.7, -7.4 mmHg4-1.04
SURMOUNT-2, obesity and type 2 diabetes, 72 weeksZepbound 10, 15 mg-5.6, -7.1 mmHg4-1.24

From Wegovy's Tables 7, 13 and 17 and Zepbound's cardiometabolic table24. People in SELECT started at 131 mmHg, and 74% already took an ACE inhibitor or ARB, two common blood-pressure medicines, which leaves less room to fall2. Rates from different trials are not a head-to-head comparison.

For a few people the fall goes too far, mostly those on blood-pressure medicine or drying out from vomiting: low blood pressure came in 1.3% on Wegovy against 0.4% on placebo, and 1.6% on Zepbound against 0.1%24. Our guide to dizziness on a GLP-1 (pepvault.app/guides/dizziness-on-a-glp-1) covers what that feels like and what helps.

What did the SELECT trial find?

SELECT asked whether semaglutide protects the heart in people who have obesity but not diabetes. It enrolled 17,604 adults aged 45 or older with a BMI of 27 or more and an earlier heart attack, stroke or narrowed leg arteries, and gave half semaglutide 2.4 mg a week and half a placebo (pepvault.app/glossary/placebo; a dummy shot), double-blind, for a mean 39.8 months5. Its main count was MACE, major adverse cardiovascular events: a heart death, a heart attack or a stroke.

Outcome in SELECTWegovy 2.4 mg (8,803)Placebo (8,801)Hazard ratio
MACE, the main count6.5%8.0%0.80
Heart attack, fatal or not2.8%3.8%0.72
Stroke, fatal or not1.8%2.0%0.89
Heart death2.5%3.0%0.85
Death from any cause4.3%5.2%0.81
Heart failure hospital stay or urgent visit1.1%1.4%0.79

From the Wegovy label's Table 62. A hazard ratio of 0.80 means the event came 20% less often over time. Only the MACE result was confirmed by the trial's testing plan; heart death fell short of confirmation, and the label states that an effect on heart failure has not been established2. The SELECT study page (pepvault.app/research/semaglutide-select-2023) has the full design.

On March 8, 2024 the FDA approved Wegovy to reduce the risk of heart attacks, strokes and heart deaths in adults with heart disease and obesity or overweight, calling it the first weight-loss medicine approved to help prevent such events6. The price was the stomach: 16.6% stopped semaglutide for a side effect, against 8.2% on placebo5. Novo Nordisk, which makes semaglutide, funded the trial5.

Is the heart benefit just the weight loss?

Not by SELECT's own analysis. A prespecified analysis found the protection the same at every starting weight, and no link between the weight a person lost in the first 20 weeks and their heart risk afterwards; in the authors' words, the protection was "independent of baseline adiposity and weight loss"7. A shrinking waist mattered more: about a third of the benefit (33%) ran through the fall in waist size, and the authors read that as "some mechanisms for benefit beyond adiposity reduction"7. Lower blood pressure is one candidate the trials measure; less inflammation is another, since C-reactive protein, a blood marker of inflammation, fell 43.5% against 7.3% on placebo in STEP-HFpEF11.

Which GLP-1 labels carry a heart-protection use?

Three of the four, each from its own outcome trial: a study built to count heart attacks, strokes and heart deaths, so it keeps thousands of people on the drug for years.

LabelHeart use, as of November 20, 2026The trial behind itResult
OzempicLower MACE in adults with type 2 diabetes and heart disease1SUSTAIN-6: 3,297 people, about 2 years, against placebo186.6% against 8.9%, hazard ratio 0.741
Wegovy (shot and tablets)Lower MACE in adults with heart disease and obesity or overweight2SELECT: 17,604 people, no diabetes, against placebo256.5% against 8.0%, hazard ratio 0.802
MounjaroLower MACE in adults with type 2 diabetes at high risk of them, added August 20263SURPASS-CVOT: 13,299 people, about 4 years, against dulaglutide (Trulicity)3912.1% against 13.0%, hazard ratio 0.92: no worse than dulaglutide, not shown better3
ZepboundNone; its uses are weight and sleep apnea4SURMOUNT-MMO, 15,374 people with obesity against placebo; the registry estimates primary completion in October 202710Not yet reported10

SURPASS-CVOT is the odd one out because it tested tirzepatide against another GLP-1 that already protects the heart, not against a dummy shot. Fewer people died of any cause on tirzepatide, 8.5% against 10.1%, a result the label marks as outside the trial's error control3. The SUSTAIN-6 study page (pepvault.app/research/semaglutide-sustain-6-2016) has the semaglutide diabetes trial, and our guide to whether GLP-1s are safe long term (pepvault.app/guides/are-glp-1s-safe-long-term) sets these trials beside the other long ones. Each brand's full label is on its page: Ozempic (pepvault.app/drugs/ozempic), Wegovy (pepvault.app/drugs/wegovy), Mounjaro (pepvault.app/drugs/mounjaro) and Zepbound (pepvault.app/drugs/zepbound).

Do GLP-1s help heart failure?

In one kind, the trials say yes. HFpEF (heart failure with preserved ejection fraction) is a stiff heart that pumps a normal share of its blood but fills poorly, leaving people breathless; obesity drives much of it. Two trials tested GLP-1s in exactly those people:

  • SUMMIT (tirzepatide up to 15 mg): 731 adults with HFpEF and a BMI of 30 or more, followed a median of 104 weeks. A heart death or worsening heart failure came in 9.9% against 15.3% on placebo (hazard ratio 0.62); worsening heart failure alone in 8.0% against 14.2%. Heart deaths were few, 8 against 5, too few to read13.
  • STEP-HFpEF (semaglutide 2.4 mg): 529 adults, 52 weeks. A 0 to 100 symptom score rose 16.6 points against 8.7, the six-minute walk lengthened 21.5 metres against 1.2, and weight fell 13.3% against 2.6%11.
  • The semaglutide pool (a post hoc analysis): across SELECT, FLOW and both STEP-HFpEF trials, 3,743 people had HFpEF; a heart death or heart failure event came in 5.4% against 7.5% (hazard ratio 0.69)12.

Neither use is on a US label. On May 1, 2025, Lilly's chief scientific officer told investors it had withdrawn its US application for tirzepatide in HFpEF because the FDA asked for another confirmatory trial, as ConscienHealth reported14; and Wegovy's label still states that an effect on heart failure has not been established2. Both companies paid for their trials1113.

Who decides whether a GLP-1 is for your heart?

Your prescriber, often with a cardiologist. The labels set the frame: the heart uses are for people who already have heart disease, or type 2 diabetes at high risk, and each sits beside the usual heart medicines rather than replacing them; in SELECT 90% also took a cholesterol-lowering drug and 86% a blood-thinning antiplatelet2. Whether a GLP-1 fits, which one, and whether a blood-pressure medicine changes as the weight comes off are the prescriber's calls. Wegovy's Medication Guide adds one routine check: your healthcare provider should check your heart rate while you take it2.

PepVault's side-effect log records a racing heart or a dizzy spell under the compound you take, with its date, a severity from minimal to very severe and a note, so your prescriber can see when it began. Log it in PepVault

When to get help Wegovy's Medication Guide puts it plainly: tell your healthcare provider if your heart races or pounds in your chest and it lasts for several minutes2.

Track it in the app

Sources

  1. Ozempic (semaglutide) injection, prescribing information (§1, §6.1 Increases in Heart Rate, §12.2 QTc, §14.2 SUSTAIN 6 and Table 9). Novo Nordisk. DailyMed, SPL version 20, effective June 1, 2026. dailymed.nlm.nih.gov
  2. Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide (§1, §5.9 Heart Rate Increase, §6.1, §14.1 Table 6 and 7, Tables 13 and 17). Novo Nordisk. DailyMed, SPL version 19, effective June 18, 2026. dailymed.nlm.nih.gov
  3. Mounjaro (tirzepatide) injection, prescribing information (§1, Recent Major Changes 08/2026, §6.1 Heart Rate Increase, §14.6 SURPASS-CVOT and Table 10). Eli Lilly and Company. DailyMed, SPL version 40, effective August 27, 2026. dailymed.nlm.nih.gov
  4. Zepbound (tirzepatide) injection, prescribing information (§1, §6.1 Heart Rate Increase and Hypotension, §14 cardiometabolic table). Eli Lilly and Company. DailyMed, SPL version 40, effective August 28, 2026. dailymed.nlm.nih.gov
  5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed 37952131
  6. US FDA. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. Press announcement, March 8, 2024. fda.gov
  7. Deanfield J et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406(10516):2257-2268. PubMed 41138739
  8. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PubMed 27633186
  9. Nicholls SJ et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025;393(24):2409-2420. PubMed 41406444
  10. ClinicalTrials.gov. SURMOUNT-MMO: tirzepatide on morbidity and mortality in adults with obesity (NCT05556512). Eli Lilly and Company. Active, not recruiting; 15,374 enrolled; primary completion estimated October 2027. Record updated November 12, 2026. clinicaltrials.gov
  11. Kosiborod MN et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity (STEP-HFpEF). N Engl J Med. 2023;389(12):1069-1084. PubMed 37622681
  12. Kosiborod MN et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. PubMed 39222642
  13. Packer M et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427-437. PubMed 39555826
  14. ConscienHealth. Lilly withdraws tirzepatide application to FDA for heart failure (reporting Lilly's chief scientific officer at its May 1, 2025 investor call). May 3, 2025. conscienhealth.org
  15. Pyke C et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280-1290. PubMed 24467746

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo